Evaluating 18F-Fluciclovine PET and MRI Imaging to Detect Tumors in Adults with Brain Metastases Undergoing Immunotherapy and Radiation

What this Trial Is About

Researchers are evaluating new imaging methods to better detect tumors in people with brain metastases. The study focuses on whether positron emission tomography PET combined with magnetic resonance imaging MRI can identify cancerous tissue more accurately than current imaging techniques. This is important for improving future cancer treatments and understanding tumor location and extent. Participants will undergo a single combined PETMRI scan using the F-Fluciclovine radiotracer, followed by a separate MRI scan using a tracer. These imaging methods use a powerful magnet, radio waves, and a computer to create detailed images and assess protein levels in tumors, which helps distinguish tumor tissue from normal brain tissue. During the study, participants will lie still for 30 to 60 minutes while imaging is performed, with the entire participation lasting about 3 hours. Researchers will measure amino acid uptake into tumor tissue during this time to evaluate the imaging effectiveness. The study is sponsored by the University of Wisconsin, Madison, and does not involve any treatment beyond imaging procedures.

18F-FLUC PET/MR in Patients With Brain Mets